Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria A Rodriguez

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Cancer|August 8, 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes projectAndrew M Evens, Ann Vanderplas, Ann S LaCasce, et al.
Leukemia & Lymphoma|March 16, 2013
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphomaBouthaina S Dabaja, Jack Phan, Osama Mawlawi, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Blood|January 12, 2012
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseAnn S LaCasce, Jonathan L Vandergrift, Maria A Rodriguez, et al.
British Journal of Haematology|October 12, 2013
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes databaseMakiko Ban-Hoefen, Ann Vanderplas, Allison L Crosby-Thompson, et al.
Cancer|April 8, 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer NetworkAlex F Herrera, Allison Crosby-Thompson, Jonathan W Friedberg, et al.
Kidney International Reports|September 21, 2020
Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart FailureTakayuki Yamada, Hiroki Ueyama, Nitin Chopra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
British Journal of Haematology|March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized StudyLoretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
JAMA Oncology|July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled TrialChelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Cancer|August 8, 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes projectAndrew M Evens, Ann Vanderplas, Ann S LaCasce, et al.
Leukemia & Lymphoma|March 16, 2013
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphomaBouthaina S Dabaja, Jack Phan, Osama Mawlawi, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
Blood|January 12, 2012
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseAnn S LaCasce, Jonathan L Vandergrift, Maria A Rodriguez, et al.
British Journal of Haematology|October 12, 2013
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes databaseMakiko Ban-Hoefen, Ann Vanderplas, Allison L Crosby-Thompson, et al.
Cancer|April 8, 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer NetworkAlex F Herrera, Allison Crosby-Thompson, Jonathan W Friedberg, et al.
Kidney International Reports|September 21, 2020
Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart FailureTakayuki Yamada, Hiroki Ueyama, Nitin Chopra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
British Journal of Haematology|March 25, 2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized StudyLoretta J Nastoupil, Peter McLaughlin, Lei Feng, et al.
JAMA Oncology|July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled TrialChelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Pageof 8